Opus Genetics Stock Technical Analysis
| IRD Stock | 2.47 0.03 1.20% |
As of the 23rd of January, Opus Genetics holds the Coefficient Of Variation of 817.04, risk adjusted performance of 0.0987, and Semi Deviation of 3.51. Opus Genetics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Opus Genetics information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Opus Genetics is priced some-what accurately, providing market reflects its current price of 2.47 per share. Please also confirm Opus Genetics total risk alpha, which is currently at (0.03) to check out the company can sustain itself at a future point.
Opus Genetics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Opus, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to OpusOpus Genetics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Opus Genetics Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 7.73 | Strong Buy | 3 | Odds |
Most Opus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Opus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Opus Genetics, talking to its executives and customers, or listening to Opus conference calls.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Opus Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Opus Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Opus Genetics.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in Opus Genetics on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding Opus Genetics or generate 0.0% return on investment in Opus Genetics over 90 days. Opus Genetics is related to or competes with Acumen Pharmaceuticals, Seer, Agenus, Inovio Pharmaceuticals, VistaGen Therapeutics, TuHURA Biosciences, and Alector. Opus Genetics is entity of United States More
Opus Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Opus Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Opus Genetics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.88 | |||
| Information Ratio | 0.0985 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 6.7 |
Opus Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Opus Genetics' standard deviation. In reality, there are many statistical measures that can use Opus Genetics historical prices to predict the future Opus Genetics' volatility.| Risk Adjusted Performance | 0.0987 | |||
| Jensen Alpha | 0.4801 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1105 | |||
| Treynor Ratio | 1.16 |
Opus Genetics January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0987 | |||
| Market Risk Adjusted Performance | 1.17 | |||
| Mean Deviation | 3.32 | |||
| Semi Deviation | 3.51 | |||
| Downside Deviation | 3.88 | |||
| Coefficient Of Variation | 817.04 | |||
| Standard Deviation | 4.35 | |||
| Variance | 18.92 | |||
| Information Ratio | 0.0985 | |||
| Jensen Alpha | 0.4801 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1105 | |||
| Treynor Ratio | 1.16 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 15.03 | |||
| Semi Variance | 12.29 | |||
| Expected Short fall | (3.75) | |||
| Skewness | 0.5914 | |||
| Kurtosis | 1.93 |
Opus Genetics Backtested Returns
Opus Genetics appears to be unstable, given 3 months investment horizon. Opus Genetics maintains Sharpe Ratio (i.e., Efficiency) of 0.0987, which implies the firm had a 0.0987 % return per unit of risk over the last 3 months. We have found twenty-six technical indicators for Opus Genetics, which you can use to evaluate the volatility of the company. Please evaluate Opus Genetics' Coefficient Of Variation of 817.04, risk adjusted performance of 0.0987, and Semi Deviation of 3.51 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Opus Genetics holds a performance score of 7. The company holds a Beta of 0.45, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Opus Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Opus Genetics is expected to be smaller as well. Please check Opus Genetics' value at risk, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Opus Genetics' historical price patterns will revert.
Auto-correlation | 0.43 |
Average predictability
Opus Genetics has average predictability. Overlapping area represents the amount of predictability between Opus Genetics time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Opus Genetics price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Opus Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | 0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Opus Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Opus Genetics Technical Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Opus Genetics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Opus Genetics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Opus Genetics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Opus Genetics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Opus Genetics price pattern first instead of the macroeconomic environment surrounding Opus Genetics. By analyzing Opus Genetics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Opus Genetics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Opus Genetics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2025 | 2026 (projected) | Interest Debt Per Share | 0.0615 | 0.0707 | 0.0672 | Revenue Per Share | 0.88 | 0.47 | 0.91 |
Opus Genetics January 23, 2026 Technical Indicators
Most technical analysis of Opus help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Opus from various momentum indicators to cycle indicators. When you analyze Opus charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0987 | |||
| Market Risk Adjusted Performance | 1.17 | |||
| Mean Deviation | 3.32 | |||
| Semi Deviation | 3.51 | |||
| Downside Deviation | 3.88 | |||
| Coefficient Of Variation | 817.04 | |||
| Standard Deviation | 4.35 | |||
| Variance | 18.92 | |||
| Information Ratio | 0.0985 | |||
| Jensen Alpha | 0.4801 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1105 | |||
| Treynor Ratio | 1.16 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 15.03 | |||
| Semi Variance | 12.29 | |||
| Expected Short fall | (3.75) | |||
| Skewness | 0.5914 | |||
| Kurtosis | 1.93 |
Opus Genetics January 23, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Opus stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | (Huge) | ||
| Rate Of Daily Change | 0.99 | ||
| Day Median Price | 2.47 | ||
| Day Typical Price | 2.47 | ||
| Price Action Indicator | (0.01) |
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |